Copy and Paste from TD Ameritrade Newswire
9:00a ET November 16, 2010 (Business Wire)
BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that the Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center, located in the metropolitan Phoenix area, has purchased a BSD-500 Hyperthermia System (BSD-500). CTCA at Western Regional Medical Center is a state-of-the-art cancer facility that provides the most advanced therapeutic resources in cancer treatment in one location (
http://www.cancercenter.com/western-hosp... CTCA is a network of hospitals and one of the premier providers of cancer care in the world. The CTCA hospitals were recently recognized by the Commission on Cancer of the American College of Surgeons as "offering the very best in cancer care." This will be the fourth BSD Hyperthermia system purchased by CTCA, including two systems purchased within the last two months.
"Hyperthermia is a highly specialized cancer treatment modality. When used in combination with external beam radiation therapy, we will be able to optimally treat a cancer with the goal of maximal containment of the disease. By having this treatment available to us, we can offer our patients the best therapeutic options available based on their particular needs," said Lanceford Chong, MD, Radiation Oncologist at CTCA.
For almost 30 years, CTCA has been on the leading edge of cancer treatment with a personalized, whole-person care model. CTCA physicians provide a full range of treatment options, including options for complex and advanced stage cases, and utilizes innovative new techniques and therapies to fight cancer on all fronts. CTCA is committed to revolutionizing cancer care by providing the most advanced and effective cancer treatments and supportive therapies available in order to treat the cancer and improve the patient's treatment experience and quality of life.
The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in conjunction with radiation therapy to treat certain tumors.
About Cancer Treatment Centers of America(R)
Founded in 1988, Cancer Treatment Centers of America (CTCA) provides a comprehensive, patient-centered treatment model that fully integrates traditional, state-of-the-art medical treatments with scientifically supported complementary therapies such as nutrition, naturopathic medicine, psychological counseling, physical therapy and spiritual support to meet the special, whole-person needs of advanced stage cancer patients. With a network of cancer treatment hospitals and community oncology programs in Arizona, Illinois, Oklahoma, Pennsylvania and Washington, CTCA encourages patients and their families to participate in treatment decisions with its Patient Empowerment Medicine(SM) model. For more information about Cancer Treatment Centers of America, go to cancercenter.com.
Thread abonnieren
